Pregabalin


Generic Medicine Info
Administration
May be taken with or without food.
Extended-release tab: Should be taken with food. Take after an evening meal. Do not split/crush/chew.
Contraindications
Hypersensitivity.
Special Precautions
Patient with diabetes, compromised respiratory function, respiratory or neurological disease, CHF, history of substance abuse, history of angioedema episodes. Patient taking CNS depressants. Avoid abrupt withdrawal (taper gradually over a minimum of 1 week). Renal impairment. Elderly. Pregnancy and lactation; avoid in pregnancy unless clearly necessary. Patient Counselling This drug may cause dizziness, drowsiness, and vision disorders, if affected, do not drive or operate machinery. Women of childbearing potential must use proven birth control methods during therapy. Monitoring Parameters Assess measures of drug efficacy (pain intensity or seizure frequency). Evaluate patients for history of substance abuse and potential for drug dependency. Obtain renal function tests (periodically); creatine kinase and platelet count (as clinically indicated). Monitor for signs and symptoms of suicidality (e.g. anxiety, suicidal thoughts, depression, behavioural changes), ocular disturbance, weight gain or oedema; respiratory depression and sedation (in patients with underlying respiratory disease).
Adverse Reactions
Significant: Hypersensitivity reactions; dizziness, somnolence, loss of consciousness, confusion, mental impairment; blurred vision, loss of vision, or other changes in visual acuity; renal failure, withdrawal symptoms; convulsions including status epilepticus and grand mal convulsions (during or shortly after discontinuation), CHF (particularly in elderly with compromised CV system), increased risk of suicidal ideation and behaviour; misuse, abuse, and dependence; peripheral oedema, weight gain, increased creatine kinase, decreased platelet count. Ear and labyrinth disorders: Vertigo. Gastrointestinal disorders: Nausea, vomiting, abdominal distension, constipation, diarrhoea, dry mouth, flatulence. General disorders and administration site conditions: Fatigue, oedema, abnormal gait, feeling drunk, fall, feeling abnormal. Metabolism and nutrition disorders: Increased appetite. Musculoskeletal and connective tissue disorders: Arthralgia, back pain, cervical spasm, muscle cramp, pain in limb. Nervous system disorders: Headache, ataxia, abnormal coordination, amnesia, balance disorder, disturbance in attention, dysarthria, hypoaesthesia, lethargy, memory impairment, paraesthesia, sedation, tremor; encephalopathy (particularly in at-risk patients). Psychiatric disorders: Disorientation, euphoric mood, insomnia, irritability. Reproductive system and breast disorders: Decreased libido, erectile dysfunction. Respiratory, thoracic and mediastinal disorders: Nasopharyngitis.
Potentially Fatal: Respiratory depression (particularly in patients with underlying respiratory impairment), angioedema with respiratory compromise.
Drug Interactions
Concomitant use with drugs that have the potential to produce constipation (e.g. opioid analgesics) may result in reduced lower gastrointestinal tract function (e.g. constipation, paralytic ileus, intestinal obstruction). May potentiate the effects of lorazepam. May increase the risk of angioedema with ACE inhibitors. Increased risk of weight gain and/or fluid retention with thiazolidinedione antidiabetic agents.
CIMS Class
Anticonvulsants / Anxiolytics / Drugs For Neuropathic Pain
ATC Classification
N02BF02 - pregabalin ; Belongs to the class of gabapentinoids. Used to relieve pain and other conditions.
Disclaimer: This information is independently developed by CIMS based on pregabalin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 CIMS. All rights reserved. Powered by CIMSAsia.com
MORE
LESS
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in